key: cord-0692061-yziiqu6b authors: Yadav, Anjali; Thakkar, Dhwanee; Wadhwa, Teena; Sarma, Smita; Upasana, K.; Rastogi, Neha; Yadav, Satya Prakash title: COVID-19 in children with blood and cancer disorders: An experience from India date: 2021-10-15 journal: Pediatric Hematology Oncology Journal DOI: 10.1016/j.phoj.2021.10.001 sha: 88599af93257ef751bf8feb26a87d6640aefb596 doc_id: 692061 cord_uid: yziiqu6b nan To the editor: Coronavirus disease-2019 is caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and has been declared as a pandemic due to rapid global spread. Children and young adults usually have milder course of illness & good outcome in comparison to adults who are elderly or have co-morbidities (1, 2) .Children with blood and cancer disorders are at high-risk of getting COVID-19 due to frequent visits to the hospital to get chemotherapy or supportive care (1) . Children with cancer are immunosuppressed and even after completion of chemotherapy, the immune dysfunction may persist for several months (3). Severe infections due to human coronaviruses (HCoV) in immunocompromised children have been reported (4) and a similar impact was expected in children on chemotherapy due to SARS-COV-2. But so far, we are still learning about impact of COVID-19 in children with blood & cancer disorders (1) . A strong association of cycle threshold (Ct) values of virus by the polymerase chain reaction (PCR) test with the severity of disease, mortality & laboratory parameters has been reported (5). In one study it was observed that replication of SARS-CoV-2 in older children leads to similar levels of viral nucleic acid as in adults, but significantly greater amounts of viral nucleic acid are detected in children younger than 5 years (6). In India, although government of India has provided a treatment protocol to manage COVID-19 but for children with COVID-19; no specific treatment has been recommended (7) . Increased morbidity and mortality have been reported in adult cancer patients with COVID-19 and also delivery of cancer care has also been affected (8) (9) (10) (11) (12) (13) (14) . We report here our experience of diagnosing and managing COVID-19 in children with blood and cancer disorders in India. We retrospectively studied outcome of children with blood & cancer disorders diagnosed with COVID-19 between February to October 2020. All were screened with nasopharyngeal swab for SARS-CoV-2 by RT-PCR prior to inpatient admission or if child had symptoms of COVID-J o u r n a l P r e -p r o o f 19 . Ct values were noted. Positive patients were isolated for atleast 14 days and retested as per hospital policy. A total of 55 patients were tested for SARS-COV-2 prior to 252 in-patient admissions. COVID-19 was detected in 13 patients. Results are shown in Table I . COVID-19 was detected in 13 patients (leukemia-3, solid tumors-7, thalassemia major-2 and aplastic anaemia-1). All were male and had median age of 8 years. SARS-COV-2 PCR was tested 369 times in these 55 patients; test positivity rate was 8.1% (30/369). Five patients who were tested by labgun kit had median Ct value of 12.74 (7.24-25.38) He died 3-weeks later due to Klebsiella sepsis. One child with Wilms tumor with Mulibrey-Nanism syndrome with atrial flutter needed intensive care but recovered fully 2 days later. Third child with brain stem glioma on ventilator got infected during radiotherapy. He restarted radiotherapy after clearance of the virus. There was mean treatment delay of 21.6 days (14-39 days). Three children had reactivation after administration of further chemotherapy. In our study, 3 children had asymptomatic reactivation during further chemotherapy and few had PCR positivity for more than 2 weeks. Out of the three children with reactivation we have previously reported 2 children (15) . In one child with neuroblastoma who had reactivation we did whole genome sequencing of the virus in samples taken from both episodes and found that it is reactivation of same virus and not a new infection (16) . As per WHO guidelines, the chances of culturing virus decline to 6% after 10 days from onset of symptoms (17) . Similar results were observed with smaller studies that recognized infectious virus can shed for 8 or 9 days (18) and others signifying correlation between Ct value/viral load and cultivable virus J o u r n a l P r e -p r o o f (18, 19) . Previous studies have reported the correlation between Ct value and disease severity (20) (21) (22) . Lower Ct values from respiratory samples were associated with more severe disease & viral load determined via Ct values correlated with disease severity (23, 24) . Our study showed that all immunocompromised patients were mostly asymptomatic irrespective of the Ct values. In contrast to previous studies, we found no significant correlation between Ct values and severity of disease in children with hemato-oncological conditions. Ct values were highly variable. In our study, a patient with case of CNS relapse of ALL treated on BFM REZ protocol and (32, 33, 34) . In our study, two patients underwent bone marrow transplant (BMT) uneventfully afer recovering from COVID-19 (autologous stem cell transplant for neuroblastoma and allogenic BMT for thalassemia). Viral reactivation was not detected. In our study, we found that planned therapy was delayed by 14 to 39 days with median value 14 days. Similar rescheduling & delay in chemotherapy has been observed in other centres too due to COVID-19 infection (35) . Varied outcomes of Covid19 in children with cancer has been reported from different parts of the world (15, 16, (35) (36) (37) (38) (39) (40) . Similar to our study most studies suggest that diagnosis of active cancer alone and recent anticancer therapy do not predict worse COVID-19 outcomes (36, 37, 39, 40) . However, few studies showed COVID-19 in paediatric patients with malignancy have reported poor outcomes compared to general population (35, 38) . COVID-19 in children with blood & cancer disorders is mostly asymptomatic and can be managed at home. However, it does lead to treatment delays and post covid complications. Ct values have wide variation and do not predict severity. Disclosure -All authors have nothing to declare COVID-19 in Children With Blood and Cancer Disorders: What Do We Know So Far? Epidemiology of COVID-19 Among Children in China Immune recovery in children with malignancy after cessation of chemotherapy Characteristics and Outcomes of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19 Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19) Clinical management protocol: COVID-19. Government of India. Ministry of Health and Family Welfare Directorate General of Health Services. Version 3. Dated 13th COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in China: a multicentre, retrospective, cohort study COVID-19 reinfection in two children with cancer Asymptomatic reactivation of SARS-CoV-2 in a child with neuroblastoma characterised by whole genome sequencing Clinical management of COVID-19: interim guidance SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory Specimens from Patients with Mild Coronavirus Disease. Emerg Infect Dis Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards Temporal dynamics in viral shedding and transmissibility of COVID-19 Chronological Changes of Viral Shedding in Adult Inpatients With COVID-19 in Wuhan, China Viral dynamics in mild and severe cases of COVID-19 Association of viral load with serum biomakers among COVID-19 cases Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical Characteristics of Coronavirus Disease 2019 in China Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series Fatal pneumonia, hyperinflammation and digital gangrene caused by human corona virus in a child post haploidentical stem cell transplant COVID-19 after hematopoietic stem cell transplantation: report of two children COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranean (POEM) group. Cancer COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: High risk of severe forms? Pediatr Blood Cancer COVID-19 in Children With Cancer Children with cancer in the time of COVID-19: An 8-week report from the six pediatric oncohematology centers in Lombardia, Italy. Pediatr Blood Cancer J o u r n a l P r e -p r o o f